Benchmark Financial Wealth Advisors LLC Has $313,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Benchmark Financial Wealth Advisors LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 15.8% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,919 shares of the company’s stock after selling 361 shares during the quarter. Benchmark Financial Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $313,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in JNJ. RKL Wealth Management LLC increased its holdings in Johnson & Johnson by 2.1% in the second quarter. RKL Wealth Management LLC now owns 48,233 shares of the company’s stock valued at $8,562,000 after purchasing an additional 1,010 shares during the last quarter. Geller Advisors LLC increased its stake in shares of Johnson & Johnson by 7.5% in the 2nd quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock valued at $1,644,000 after acquiring an additional 648 shares during the last quarter. Simon Quick Advisors LLC raised its position in shares of Johnson & Johnson by 296.9% in the 2nd quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock valued at $1,495,000 after acquiring an additional 6,537 shares during the period. Lokken Investment Group LLC grew its holdings in Johnson & Johnson by 1.6% during the second quarter. Lokken Investment Group LLC now owns 12,968 shares of the company’s stock valued at $2,302,000 after purchasing an additional 201 shares during the period. Finally, Keebeck Alpha LP increased its stake in Johnson & Johnson by 13.4% in the second quarter. Keebeck Alpha LP now owns 4,442 shares of the company’s stock valued at $788,000 after purchasing an additional 525 shares in the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Insider Transactions at Johnson & Johnson

In related news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares in the company, valued at $6,431,835.20. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, insider William Hait sold 15,000 shares of Johnson & Johnson stock in a transaction dated Monday, October 24th. The stock was sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the completion of the transaction, the insider now owns 80,236 shares in the company, valued at $13,764,485.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the sale, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The disclosure for this sale can be found here. Insiders have sold a total of 277,886 shares of company stock worth $48,550,549 in the last 90 days. Corporate insiders own 0.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on JNJ shares. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. Barclays started coverage on Johnson & Johnson in a report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price target for the company. StockNews.com assumed coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Raymond James dropped their target price on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a report on Wednesday, October 19th. Finally, Citigroup increased their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $181.75.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $168.74 on Friday. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The stock has a market capitalization of $441.17 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 3.28 and a beta of 0.56. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The business has a 50-day moving average of $176.14 and a 200-day moving average of $171.25.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.68%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is 62.95%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.